Related Experiment Video
Updated: Sep 20, 2026
miRNA Expression Analyses in Prostate Cancer Clinical Tissues
Published on: September 8, 2015
mRNA expression profile of matrix metalloproteinases and their tissue inhibitors in malignant and non-malignant
Ralf Lichtinghagen1, Petra B Musholt, Carsten Stephan
1Department of Clinical Chemistry, University Medical School, Hannover, Germany.
Background:
Increased expression of matrix metalloproteinases (MMPs) was found in various carcinomas. The aim of this study was to present a comprehensive mRNA expression profile of MMPs in benign and malignant prostatic tissue.
Materials And Methods:
mRNA expression patterns of MMP-1, -2, -7, -9, -11, -14 and their tissue inhibitors (TIMPs) -1, -2 and -3 were studied in cancerous and non-cancerous parts of 17 prostates removed by radical prostatectomy. Competitive reverse transcritpion PCR was used for quantification of MMP and TIMP mRNA.
Results:
Both decreased (MMP-2, MMP-11, MMP-14) and a tendency to increased (MMP-9) MMP values in cancerous compared to the non-cancerous samples were observed. Significantly reduced TIMP-2 and TIMP-3 values were remarkable. Relatively strong associations were found among the three TIMPs while only a significant correlation between MMPs was observed between MMP-2 and MMP-7. There were no significant correlations between MMPs and tumor grade and stage and serum prostate-specific antigen. Receiver operation characteristic analyses proved that MMP and TIMP mRNA and their ratios have an insufficient capability to differentiate between cancerous and non-cancerous tissue. The ratios of MMP-9 to all three TIMPs and the ratio of MMP-14 to TIMP-3 were significantly increased.
Conclusion:
These increased ratios support the view of an imbalance between MMP-9 activity and its inhibitory counterparts in cancerous tissue as an important step in the development of prostate carcinoma and implicate the rationale of using synthetic inhibitors of MMPs as potential therapeutic tools.
Insights
Matrix metalloproteinase (MMP) and tissue inhibitor (TIMP) mRNA levels were analyzed in prostate cancer. Increased MMP-9 to TIMP ratios suggest an imbalance in cancerous tissue, potentially offering therapeutic targets.
Area of Science:
- Oncology
- Molecular Biology
- Biochemistry
Background:
- Matrix metalloproteinases (MMPs) are implicated in various carcinomas.
- Understanding MMP expression in prostate tissue is crucial for cancer research.
Purpose of the Study:
- To comprehensively profile mRNA expression of MMPs and their inhibitors (TIMPs) in benign and malignant prostate tissue.
- To investigate the relationship between MMP/TIMP expression and clinicopathological features of prostate cancer.
Main Methods:
- Quantitative analysis of MMP-1, -2, -7, -9, -11, -14 and TIMP-1, -2, -3 mRNA expression using competitive reverse transcription PCR.
- Analysis of 17 radical prostatectomy specimens comparing cancerous and non-cancerous tissue.
Main Results:
- Observed decreased mRNA levels for MMP-2, MMP-11, and MMP-14, with a trend towards increased MMP-9 in cancerous tissue.
- Significantly reduced TIMP-2 and TIMP-3 mRNA levels were noted in malignant samples.
- Significantly increased ratios of MMP-9 to TIMPs and MMP-14 to TIMP-3 were found in cancerous tissue, despite insufficient diagnostic capability of individual markers.
Conclusions:
- The elevated MMP-9 to TIMP ratios indicate a functional imbalance in protease activity within prostate cancer.
- This imbalance highlights the potential of targeting MMPs, particularly MMP-9, as a therapeutic strategy for prostate carcinoma.
- Further research into MMP inhibitors may offer novel treatment avenues for prostate cancer.
Related Concept Videos
01:23Role of Matrix Metalloproteases in Degradation of ECM
A...
01:22MicroRNAs
01:22MicroRNAs